Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$7.51 -1.1%	$6.72	$5.64 ▼ $16.76	$777.46M	-1.26	2.08 million shs	893,899 shs
MBX MBX Biosciences	$15.09 +5.7%	$12.95	$4.81 ▼ $27.50	$506.93M	N/A	324,882 shs	154,165 shs
PRAX Praxis Precision Medicines	$45.54 -1.0%	$49.18	$26.70 ▼ $91.83	$967.90M	2.62	508,628 shs	275,873 shs
RCUS Arcus Biosciences	$10.60 -0.1%	$9.42	$6.50 ▼ $18.98	$1.13B	0.89	759,613 shs	548,275 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	-1.05%	+4.31%	+9.32%	+17.53%	-46.43%
MBX MBX Biosciences	+5.75%	+5.30%	-2.58%	+20.43%	+1,508,999,900.00%
PRAX Praxis Precision Medicines	-0.98%	-6.64%	-19.53%	+18.04%	-10.81%
RCUS Arcus Biosciences	-0.19%	+0.82%	+12.59%	+17.98%	-38.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	2.5138 of 5 stars	3.6	2.0	3.2	2.5	0.0
MBX MBX Biosciences	2.6308 of 5 stars	3.5	0.0	3.4	1.7	0.6
PRAX Praxis Precision Medicines	1.6875 of 5 stars	3.4	1.0	2.8	1.7	0.0
RCUS Arcus Biosciences	2.3456 of 5 stars	3.4	3.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	236.69% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	149.34% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	88.57% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	99.56% Upside

Current Analyst Ratings Breakdown

Latest MBX, PRAX, RCUS, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$187.64M	4.10	N/A	N/A	$4.50 per share	1.67
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	$8.55M	112.12	N/A	N/A	$19.21 per share	2.37
RCUS Arcus Biosciences	$258M	4.37	N/A	N/A	$5.16 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)

Latest MBX, PRAX, RCUS, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
MBX MBX Biosciences	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	6.31	6.31
RCUS Arcus Biosciences	0.18	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
MBX MBX Biosciences	N/A
PRAX Praxis Precision Medicines	67.84%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
MBX MBX Biosciences	52.19%
PRAX Praxis Precision Medicines	2.70%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable

MBX, PRAX, RCUS, and DAWN Headlines

Recent News About These Companies

Campbell & CO Investment Adviser LLC Makes New $1.30 Million Investment in Arcus Biosciences, Inc. $RCUS

August 29 at 5:20 AM | marketbeat.com

Swiss National Bank Boosts Stake in Arcus Biosciences, Inc. $RCUS

August 28 at 3:26 AM | marketbeat.com

Vanguard Group Inc. Has $52.50 Million Position in Arcus Biosciences, Inc. $RCUS

August 28 at 3:11 AM | marketbeat.com

Arcus Biosciences, Inc. $RCUS Stock Holdings Lifted by Algert Global LLC

August 24, 2025 | marketbeat.com

Arcus Biosciences, Inc. $RCUS Shares Purchased by Public Sector Pension Investment Board

August 24, 2025 | marketbeat.com

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 22, 2025 | theglobeandmail.com

Gilead Sciences Inc. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS)

August 19, 2025 | marketbeat.com

Jim Cramer on Arcus Biosciences: “Let This Be Your Speculation”

August 16, 2025 | finance.yahoo.com

Cramer's Lightning Round: Uranium Energy is a buy

August 14, 2025 | msn.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 12, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings

August 11, 2025 | marketbeat.com

Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst

August 11, 2025 | marketbeat.com

Leerink Partnrs Has Negative Estimate for RCUS Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Forecasts Lower Earnings for Arcus Biosciences

August 11, 2025 | marketbeat.com

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

August 10, 2025 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Wedbush Decreases Earnings Estimates for Arcus Biosciences

August 9, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Price Target Lowered to $25.00 at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Gilead hands back one Arcus cancer candidate from $725M deal

August 7, 2025 | fiercebiotech.comF

Arcus (RCUS) Q2 Revenue Jumps 310%

August 6, 2025 | fool.com

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

August 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX, PRAX, RCUS, and DAWN Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$7.51 -0.08 (-1.05%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.50 0.00 (-0.07%)

As of 08/29/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

MBX Biosciences NYSE:MBX

$15.09 +0.82 (+5.75%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$15.04 -0.05 (-0.33%)

As of 08/29/2025 07:57 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Praxis Precision Medicines NASDAQ:PRAX

$45.54 -0.45 (-0.98%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$45.52 -0.02 (-0.05%)

As of 08/29/2025 05:38 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Arcus Biosciences NYSE:RCUS

$10.60 -0.02 (-0.14%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$10.60 +0.00 (+0.04%)

As of 08/29/2025 06:09 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time